These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38838294)

  • 21. Buprenorphine MAT as an Imperfect Fix.
    Mund B; Stith K
    J Law Med Ethics; 2018 Jun; 46(2):279-291. PubMed ID: 30147005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Injectable Buprenorphine: An Opportunity to Improve Treatment Access for Youth With Opioid Use Disorder.
    Calihan JB; Bagley SM
    J Adolesc Health; 2024 Jul; 75(1):13-14. PubMed ID: 38880557
    [No Abstract]   [Full Text] [Related]  

  • 23. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Yan K
    N Engl J Med; 2017 Mar; 376(10):1000. PubMed ID: 28276662
    [No Abstract]   [Full Text] [Related]  

  • 24. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Sigmon SC; Schwartz RP; Higgins ST
    N Engl J Med; 2017 Mar; 376(10):1000-1001. PubMed ID: 28273017
    [No Abstract]   [Full Text] [Related]  

  • 25. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
    Balhara YP
    J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
    [No Abstract]   [Full Text] [Related]  

  • 26. Overcoming Barriers to Treatment of Opioid Use Disorder.
    Olsen Y; Fitzgerald RM; Wakeman SE
    JAMA; 2021 Mar; 325(12):1149-1150. PubMed ID: 33630021
    [No Abstract]   [Full Text] [Related]  

  • 27. Does the advent of depot therapy represent a step change in our understanding of opioid use disorder and its treatment?
    Roberts E; Humphreys K
    Drug Alcohol Rev; 2024 Jan; 43(1):261-264. PubMed ID: 37525510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low- and very low-dose buprenorphine induction: new(ish) uses for an old(ish) medication?
    Weimer MB; Fiellin DA
    Addiction; 2022 Jun; 117(6):1507-1509. PubMed ID: 35032081
    [No Abstract]   [Full Text] [Related]  

  • 30. Datapoints: regional variation in benzodiazepine prescribing for patients on opioid agonist therapy.
    Park TW; Bohnert AS; Austin KL; Saitz R; Pizer SD
    Psychiatr Serv; 2014 Jan; 65(1):4. PubMed ID: 24382761
    [No Abstract]   [Full Text] [Related]  

  • 31. Rapid Access to Medications for Opioid Use Disorder.
    Kleinman RA; Morris NP
    J Gen Intern Med; 2021 Nov; 36(11):3557-3558. PubMed ID: 34047923
    [No Abstract]   [Full Text] [Related]  

  • 32. Using buprenorphine to treat patients with opioid use disorder.
    Radi JK; Fogarty KJ; Lagerwey MD
    JAAPA; 2019 Oct; 32(10):30-35. PubMed ID: 31513035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Legal Authority for Emergency Medical Services to Increase Access to Buprenorphine Treatment for Opioid Use Disorder.
    Davis CS; Carr DH; Glenn MJ; Samuels EA
    Ann Emerg Med; 2021 Jul; 78(1):102-108. PubMed ID: 33781607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buprenorphine Initiation: Low-Dose Methods #457.
    Ho JJ; Jones KF; Merlin JS; Sager Z; Childers J
    J Palliat Med; 2023 Jun; 26(6):867-869. PubMed ID: 37276524
    [No Abstract]   [Full Text] [Related]  

  • 35. The Number Needed to Prescribe - What Would It Take to Expand Access to Buprenorphine?
    Poorman E
    N Engl J Med; 2021 May; 384(19):1783-1784. PubMed ID: 33983689
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevention of Opioid Overdose.
    Babu KM; Brent J; Juurlink DN
    N Engl J Med; 2019 Jun; 380(23):2246-2255. PubMed ID: 31167053
    [No Abstract]   [Full Text] [Related]  

  • 37. Managing emergency department patients with opioid use disorder.
    Hazekamp CS; Sacco D
    Emerg Med Pract; 2024 Jun; 26(6):1-24. PubMed ID: 38768011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innovations in efforts to expand treatment for opioid use disorder.
    Sigmon SC
    Prev Med; 2019 Nov; 128():105818. PubMed ID: 31445112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

  • 40. The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019-2022: longitudinal sales data analysis.
    Lintzeris N; Hayes V; Dunlop AJ
    Med J Aust; 2024 Apr; 220(6):339-340. PubMed ID: 38438113
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.